Clinical Trials Browser

Phase 1 × Completed × Neoplasm, Residual × Clear all

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT04853017 2025-09-05

AMPLIFY-201

Bile Duct Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Neoplasm, Residual

NCT03524235 2024-11-12

Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL

Phase 1 Completed

20 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Lymphoma, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm, Residual

NCT02185781 2023-03-30

Phase I Study of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL)

Phase 1 Completed

6 enrolled

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02529813 2022-06-30

CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies

Phase 1 Completed

26 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01460498 2020-03-05

Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

Phase 1 Completed

3 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

Clinical Trials

Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia

AMPLIFY-201

Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL

Phase I Study of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL)

CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies

Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)